Results 61 to 70 of about 8,919 (185)
Management of epidermolysis bullosa simplex in pregnancy: A case report
Case Reports in Women's Health, 2019 Epidermolysis bullosa (EB) encompasses a group of diseases characterized by extreme fragility of skin and mucous membranes, resulting in blister formation following minimal injury.
Nidhi Shah +2 more
doaj +1 more source
Delivery Systems for Therapeutic Genome Editing: Challenges, Innovations, and Future Perspectives
MedComm, Volume 7, Issue 7, July 2026.Schematic illustration of four emerging CRISPR–Cas delivery platforms defined by distinct design principles and structural features: virus‐mimicking nanosystems (e.g., VLPs), cell‐derived extracellular vesicles, cell‐penetrating peptides, and stimuli‐responsive scaffolds. These platforms enable spatiotemporally controlled delivery of RNPs, mRNA, or DNA
Meijia Yang +9 more
wiley +1 more source
Junctional Epidermolysis Bullosa
Journal of the Chinese Medical Association, 2006 Epidermolysis bullosa (EB) encompasses a heterogeneous group of genodermatoses, characterized by fragility and blistering of the skin, often associated with extracutaneous manifestations. The level of vesiculation within the skin defines 3 major subtypes of EB: EB simplex, junctional EB, and dystrophic EB.
Kao, Chuan-Hong +5 more
openaire +2 more sources
Modern methods of the treatment of hereditary epidermolysis bullosa
Vestnik Dermatologii i Venerologii, 2017 Today there are no ethiopathogenetic treatment methods for treating hereditary epidermolysis bullosa. All available treatment methods are symptomatic and are mainly aimed at patient care.
A. A. Kubanov +3 more
doaj +1 more source
Aging Cell, Volume 25, Issue 7, July 2026.This review systematically elucidates the multifactorial anti‐aging mechanisms of extracellular vesicles (EVs). By bridging fundamental biology with advanced bioengineering, scalable manufacturing, and clinical translation, it establishes a comprehensive framework for developing next‐generation EVs‐based precision nanotherapeutics to combat systemic ...
Xian Huang +6 more
wiley +1 more source
A pathogenic COL7A1 variant highlights semi-dominant inheritance in dystrophic epidermolysis bullosa
BMC Medical GenomicsDystrophic epidermolysis bullosa is a rare subtype of inherited epidermolysis bullosa, caused by variants in the collagen type VII alpha 1 chain (COL7A1) gene (MIM120120).
Saira Sattar +6 more
doaj +1 more source
Hematology, Transfusion and Cell TherapyIntroduction: Secondary thrombocytosis is a well-recognized response to chronic inflammation, infections, and systemic disorders, but its association with dermatologic diseases such as Norwegian scabies and epidermolysis bullosa is rare.
Mine Ezgi Payaslı +3 more
doaj +1 more source
The puzzling effect of disease severity on quality of life in epidermolysis bullosa
Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 8, Page e665-e668, August 2026.
Vinzenz Hübl +4 more
wiley +1 more source
Real‐World Experience With Oleogel‐S10 for Wounds in Epidermolysis Bullosa
JEADV Clinical PracticeBackground Oleogel‐S10 is the first approved drug for the treatment of wounds in patients with junctional and dystrophic epidermolysis bullosa. Results from the clinical trials, early access programme and open‐label study are available, showing good ...
Miodrag Davidovic +2 more
doaj +1 more source
The Application of Clinical Genetics, 2021 Sang Trieutien,1,* Tam Vu Van,2,3,* My Tran Ngoc Thao,4 Son Trinh The,5 Khoa Tran Van,1 Tung Nguyen Thanh,5 Tuan Tran Van,5 Hanh Nguyen Thi6 1Department of Biology and Genetics, Vietnam Military Medical University, Hanoi, 12108, Vietnam ...
Trieutien S +7 more
doaj